GW Pharmaceuticals PLC (GWPH.OQ)
16 Feb 2018
Tue, Feb 6 2018
BRIEF-GW Pharmaceuticals Announces EMA Accepts Epidiolex Marketing Authorization Application For Review
* GW PHARMACEUTICALS ANNOUNCES THE EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS EPIDIOLEX® (CANNABIDIOL) MARKETING AUTHORIZATION APPLICATION (MAA) FOR REVIEW
* GW PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF NDA FILING FOR EPIDIOLEX® (CANNABIDIOL) IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME AND DRAVET SYNDROME Source text for Eikon: Further company coverage:
* GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S.
BRIEF-GW Pharmaceuticals Announces Pricing Of Public Offering Of ADSs Raising Gross Proceeds Of $276 Million
* GW PHARMACEUTICALS PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS RAISING GROSS PROCEEDS OF $276 MILLION
* GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS
Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .
* Analyst expects drug to become standard in Dravet treatment
- Growing Ganja In Gatineau: Can Hydropothecary Dominate Quebec Cannabis?
- Your Daily Pharma Scoop: GW Pharmaceuticals Pullback, Seattle Genetics Announces Collaboration Agreement, Catalyst Reports Data
- Hottest U.S. Marijuana ETF Risks Facing Closure
- 268 Marijuana Stocks: Learn From An Examination Of Event Dates For The Prior 52 Weeks
- Your Daily Pharma Scoop: Nabriva Pullback, GW Pharmaceuticals Makes Progress, ContraVir Announces Promising Results
- GW Pharmaceuticals' (GWPH) CEO Justin Gover on Q1 2018 Results - Earnings Call Transcript